- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04172441
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
March 13, 2023 updated by: Zealand Pharma
A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism
The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hypoglycemia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Düsseldorf, Germany, 40225
- University Children's Hospital
-
Magdeburg, Germany, 39120
- University Hospital, Magdeburg
-
-
-
-
-
Jerusalem, Israel, 9765422
- Hadassah Medical Center
-
-
-
-
-
Manchester, United Kingdom, M13 9WL
- Manchester University NHS Foundation Trust
-
-
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Cook Children's Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 week to 11 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
CHI diagnosis established based on the following:
- Hyperinsulinemia: plasma insulin above the limit of detection of the assay documented during an event of hypoglycemia, and/or
- Hypofattyacidemia: plasma free fatty acid <1.7 mmol/L, and/or
- Hypoketonemia: Beta-hydroxybutyrate <1.8 mmol/L, and/or
- Glycemic response: an increase in PG of >30 mg/dL (1.7 mmol/L) after 1 mg IV or intramuscular (IM) glucagon administration
- Male or female, age ≥7 days and <12 months at screening
- Body weight of ≥2.0 kg (4.4 lbs.)
- Continuous IV glucose requirement to prevent hypoglycemia
Exclusion Criteria:
- Is suspected of having a transient form of CHI (e.g., transient hyperinsulinism due to maternal diabetes or perinatal stress)
- Was born preterm below 34 weeks of gestational age
- Presence of hypertension or hypotension, including circulatory instability requiring supportive medication or presence of pheochromocytoma
- Known or suspected presence of severe brain damage
- Evidence of metabolic, endocrine, or syndromic causes of hypoglycemia not due to hyperinsulinism
- Use of systemic corticosteroids, e.g., hydrocortisone >20 mg/m2 body surface area or equivalent within 5 days before screening
- Prior use of lanreotide, sirolimus (mechanistic target of rapamycin (mTOR) inhibitors), anti inflammatory biological agents, or other immune modulating agents. Prior use of octreotide is allowed after a minimum of 48 hour washout before randomization.
- Any clinically significant abnormality identified on echocardiogram that in the opinion of the investigator would affect the subject's ability to participate in the trial
- Any recognized clotting or bleeding disorder
- The use of prescription or non-prescription medications known to cause QT prolongation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dasiglucagon first then placebo
48 hours of dasiglucagon subcutaneous (sc) infusion starting at 10 µg/hour with crossover to 48 hours placebo sc infusion (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
|
Placebo for dasiglucagon
Glucagon analogue
Other Names:
|
Experimental: placebo first then dasiglucagon
48 hours of placebo sc infusion with crossover to 48 hours dasiglucagon sc infusion starting at 10 µg/hour (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
|
Placebo for dasiglucagon
Glucagon analogue
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean intravenous glucose infusion rate
Time Frame: 36-48 hours after initiation of trial drug
|
Mean intravenous glucose infusion rate in the last 12 hours of each treatment period during the crossover part of the trial (dasiglucagon or placebo administration)
|
36-48 hours after initiation of trial drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Carbohydrates administered
Time Frame: 0-48 hours after initiation of trial drug
|
Total amount (g) of carbohydrates administered during the crossover part of the trial (dasiglucagon or placebo administration) per day
|
0-48 hours after initiation of trial drug
|
Carbohydrates administered
Time Frame: 0-48 hours after initiation of trial drug
|
Mean intravenous glucose infusion rate for each 48-hour treatment period during the crossover part of the trial (dasiglucagon or placebo administration)
|
0-48 hours after initiation of trial drug
|
Carbohydrates administered
Time Frame: 36-48 hours after initiation of trial drug
|
Mean intravenous glucose infusion rate below 10 mg/kg/min in the last 12 hours of each treatment period during the crossover part of the trial (yes/no) (dasiglucagon or placebo administration)
|
36-48 hours after initiation of trial drug
|
Time to complete weaning off intravenous glucose
Time Frame: Day 5-25
|
Time to complete weaning off intravenous glucose administration during part 2
|
Day 5-25
|
Hypoglycemia event rate in part 2
Time Frame: Day 5-25
|
Hypoglycemia event rate, defined as number of hypoglycemic events (PG <70 mg/dL or 3.9 mmol/L), as detected by self-monitored plasma glucose
|
Day 5-25
|
Clinically significant hypoglycemia events in part 2
Time Frame: Day 5-25
|
Clinically significant hypoglycemia event rate, defined as number of events <54 mg/dL (3.0 mmol/L), as detected by self-monitored plasma glucose
|
Day 5-25
|
Time to actual hospital discharge
Time Frame: Day 5-25
|
Time (days) from start of part 2 until the patient is discharged from the hospital
|
Day 5-25
|
Time to pancreatic surgery
Time Frame: Day 5-25
|
Time (days) to pancreatic surgery (sub-total or total pancreatectomy)
|
Day 5-25
|
Carbohydrates administered
Time Frame: Day 5-25
|
Total amount (g) of carbohydrates administered (regardless of the route) per day
|
Day 5-25
|
Carbohydrates administered intravenously
Time Frame: Day 5-25
|
Amount (g) of carbohydrates administered via IV glucose infusion or bolus (not as part of total parental nutrition)
|
Day 5-25
|
Carbohydrates administered parenterally
Time Frame: Day 5-25
|
Amount (g) of carbohydrates administered as part of total parenteral nutrition
|
Day 5-25
|
Carbohydrates administered orally
Time Frame: Day 5-25
|
Amount (g) of carbohydrates administered via oral route
|
Day 5-25
|
Carbohydrates administered via gastric feed
Time Frame: Day 5-25
|
Amount (g) of carbohydrates administered via nasogastric tube or gastrostomy
|
Day 5-25
|
Time in range in part 2
Time Frame: Day 5-25
|
Percent time in range 70-180 mg/dL (3.9-10.0
mmol/L) as measured by continuous glucose monitoring
|
Day 5-25
|
Time in hypoglycemia in part 2
Time Frame: Day 5-25
|
Percent time in hypoglycemia (<70 mg/dL or 3.9 mmol/L) as measured by continuous glucose monitoring
|
Day 5-25
|
Time in clinically significant hypoglycemia in part 2
Time Frame: Day 5-25
|
Percent time in clinically significant hypoglycemia (<54 mg/dL or 3.0 mmol/L) as measured by continuous glucose monitoring
|
Day 5-25
|
Hypoglycemia episodes in part 2
Time Frame: Day 5-25
|
Rate of hypoglycemia episodes, defined as number of episodes <70 mg/dL (3.9 mmol/L) for 15 min or more, as measured by continuous glucose monitoring
|
Day 5-25
|
Clinically significant hypoglycemia episodes in part 2
Time Frame: Day 5-25
|
Rate of clinically significant hypoglycemia episodes, defined as number of episodes <54 mg/dL (3.0 mmol/L) for 15 min or more, as measured by continuous glucose monitoring
|
Day 5-25
|
Extent of hypoglycemia in part 2
Time Frame: Day 5-25
|
Extent of hypoglycemia (area over the glucose curve [AOCglucose] below 70 mg/dL [3.9 mmol/L]) as measured by continuous glucose monitoring
|
Day 5-25
|
Extent of clinically significant hypoglycemia in part 2
Time Frame: Day 5-25
|
Extent of clinically significant hypoglycemia (area over the glucose curve [AOCglucose] below 54 mg/dL [3.0 mmol/L]) as measured by continuous glucose monitoring
|
Day 5-25
|
Time in hyperglycemia in part 2
Time Frame: Day 5-25
|
Percent time in hyperglycemia (>180 mg/dL or 10.0 mmol/L), as measured by continuous glucose monitoring
|
Day 5-25
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 22, 2020
Primary Completion (Actual)
March 7, 2022
Study Completion (Actual)
March 7, 2022
Study Registration Dates
First Submitted
November 18, 2019
First Submitted That Met QC Criteria
November 18, 2019
First Posted (Actual)
November 21, 2019
Study Record Updates
Last Update Posted (Actual)
March 15, 2023
Last Update Submitted That Met QC Criteria
March 13, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZP4207-17103
- 2017-004545-24 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Hyperinsulinism
-
University Medicine GreifswaldCompletedNon-focal Congenital HyperinsulinismGermany
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaCompletedPersistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) | Congenital Hyperinsulinism (CHI)United States
-
Beijing Children's HospitalCompletedCongenital Hyperinsulinaemic Hypoglycaemia | Octreotide Adverse ReactionChina
-
University Hospital, Basel, SwitzerlandGottfried und Julia Bangerter-Rhyner-StiftungCompletedEndogenous HyperinsulinismSwitzerland
-
Miguel PampaloniRecruitingCongenital HyperinsulinismUnited States
-
Zealand PharmaCompletedCongenital HyperinsulinismUnited States, United Kingdom, Germany, Israel
-
Montefiore Medical CenterNo longer availableCongenital HyperinsulinismUnited States
-
Diva De LeonTerminatedCongenital HyperinsulinismUnited States
-
Diva De LeonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedCongenital HyperinsulinismUnited States
-
Assistance Publique - Hôpitaux de ParisNovartisCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy